Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Deciphering P. falciparum artemisinin resistance in Bangladesh: a genotypic-phenotypic evaluation of Kelch13 dependent and independent determinants

Award Number: R21AI180663
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/31/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Deciphering P. falciparum artemisinin resistance in Bangladesh: a genotypic-phenotypic evaluation of Kelch13 dependent and independent determinants - Summary/Abstract Malaria control and elimination face significant challenges due to drug resistance, particularly to the current front-line artemisinin-based combination therapy in the Greater Mekong Region, to artemisinin (ART) derivatives in Myanmar and now disturbingly in eastern Africa where most serious falciparum malaria cases are concentrated. To ensure the continued effectiveness of ART and its partner drugs, early detection and characterization of resistance, robust surveillance and subsequent isolation are required. World-wide clinical and molecular surveillance of artemisinin resistance (ART-R) relies on southeast Asian characteristics of longer parasite clearance times from patients and genotyping for mutations in the most common ART resistant gene, k13 (a gene on chromosome 13 coding for a kelch domain protein, K13). The Chittagong Hill Tracts (CHTs) in Bangladesh borders Myanmar, and is a forested, hilly and remote region that is endemic to 90% of the country’s malaria. Recent clinical clearance and in vitro assays not only in the CHTs but also in Africa demonstrate that although combination treatment remains efficacious in infected patients, a cohort of the field isolates display in vitro low-moderate ART-R with no K13 mutations. This suggests that clones with partial ART-R exist and are going undetected by patient parasite clearance studies and molecular surveillance. Proactive analysis of the impact of these molecular determinants will be critical to characterize resistance before the problem is widespread in these regions in the pre-elimination era. We hypothesize that 1) Clinical ART resistant mutations can be predicted from in vitro generated mutants in isolates from the same spatiotemporal space. 2) ART sensitivity is changing in the CHTs with continued use of artemisinin combination therapy since 2004. The initial low-moderate ART-R mediated by causal K13 independent mutations will be an optimal platform for highly resistant and highly fit K13 mutations to arise and spread. We will test our hypotheses with two specific aims. In Aim 1, we will perform whole-genome sequencing of in vitro evolved K13 independent ART-R in recent CHT isolates; in parallel determine the drug sensitivities and genomic sequences of parasites recently isolated from CHT patients and functionally validate top candidate genes by CRISPR-Cas9 editing. In Aim 2, we will perform preemptive resistance and fitness cost analysis of major K13 mutations in the K13 independent ART resistant and ART sensitive CHT genetic backgrounds, to determine if these “unknown factors” assist the resistance potential and sustainability of these K13 mutations. Together, this study will provide a comprehensive view of the complex emerging ART-R with a broader applicability to similar scenarios in Eastern Africa.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	UNIVERSITY OF NOTRE DAME DU LAC	940 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	2	1/16/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $234,750 )
2025	2025	UNIVERSITY OF NOTRE DAME DU LAC	940 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	2	4/9/2025	NON-COMPETING CONTINUATION	$234,750
														Subtotal = $234,750

Issue Date FY: 2024 ( Subtotal = $195,625 )
2024	2024	UNIVERSITY OF NOTRE DAME DU LAC	940 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	002	1	9/11/2024	NEW	$0
2024	2024	UNIVERSITY OF NOTRE DAME DU LAC	836 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	1	5/31/2024	NEW	$176,063
2024	2024	UNIVERSITY OF NOTRE DAME DU LAC	836 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	001	1	7/26/2024	NEW	$19,562
														Subtotal = $195,625

Grand Total All Awards = $430,375

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Deciphering P. falciparum artemisinin resistance in Bangladesh: a genotypic-phenotypic evaluation of Kelch13 dependent and independent determinants

Award Number: R21AI180663

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/31/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer